Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text

Medicine, Molecular Genetics, Oncology +9

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations

Medicine, Oncology, Pharmacology +11

<i>BRAF</i> Mutations in Hairy-Cell Leukemia

Enrico Tiacci, Gianluca Schiavoni, Antony B. Holmes et al. · New England Journal of Medicine · 2011 · 1K citations · Full text

Medicine, Genetics, Oncology +17

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

Enrico Tiacci, Jae H. Park, Stephen S. Chung et al. · New England Journal of Medicine · 2015 · 342 citations · Full text

Medicine, Oncology, Pharmacology +8

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Michael R. Grever, Omar Abdel‐Wahab, Leslie A. Andritsos et al. · Blood · 2016 · 289 citations · Full text

Medicine, Hematology, Oncology +10